DNA
Ginkgo Bioworks Holdings, Inc. (DNA)
Healthcare • Biotechnology • $6.95 • MCap: 468,014,944
🌐
https://www.ginkgo.bio • Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Buy Decision Core
Total Score
33
Business Quality
10
Financial Strength
5
Growth Outlook
1
Momentum
0
Price Action
Current
6.95
52W High
16.14
52W Low
5.48
Above 50DMA
8.11 (-14.35%)
Above 200DMA
8.31 (-16.38%)
Relative Strength
Relative Strength
-0.16
RS 3M
-0.15
RS 6M
0.07
RS 9M
-0.23
RS 12M
-0.35
Fundamentals
Revenue Growth
-0.48%
Earnings Growth
0%
ROE
-0.60%
ROA
-0.17%
Valuation
PE (Fwd)
-2.40
PEG
0
P/B
1.05
Upside
0.72%
Risk
Beta
1.77
Short %
0.10
Risk Score
10.00
Analyst
Rating
none
Target
7.00
Beta
1.77
Analysts
0
Total Score
33
Upside
0.72%
Relative Strength
-0.16
Beta
1.77
Why Buy?
- PEG Ratio below 1 (attractive valuation)
Key Risks
- Revenue growth is negative
- Negative ROE
- High volatility (Beta > 1.5)
- Weak long-term relative strength
Score Breakdown
Business
10
10
Financial
5
5
Growth
1
1
Valuation
12
12
Risk
2
2
Momentum
0
0
Technical
52W High: 16.14
52W Low: 5.48
Above 50DMA: -14.35%
Above 200DMA: -16.38%
Valuation
Forward PE: -2.40
PEG: 0
P/B: 1.05
Upside: 0.72%
Risk
Beta: 1.77
Short Float: 0.10%
ROE: -0.60%
ROA: -0.17%